Sage Journals: Discover world-class research

Retricted access

Review article

First published 2020-7

The limitations of today’s clinical guidance: Atypical femoral fracture and long-term bone-modifying agents in the oncology setting

Edna Cheung, Hala T Borno

Journal of Oncology Pharmacy Practice

Open access

Case report

First published 2017-9

Atypical femoral fracture associated with bone-modifying agent for bone metastasis of breast cancer: A report of two cases

Daisuke Tateiwa, Hidetatsu Outani, Saya Iwasa [...]

Journal of Orthopaedic Surgery

Retricted access

Research article

First published 2022-4

Safety and efficacy of bone-modifying agents among multiple myeloma patients: A retrospective cohort study

Christina Billias, Megan Langer, Sorana Ursu [...]

Journal of Oncology Pharmacy Practice

Retricted access

Editorial

First published 2025-10

The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives

Alberto Zambelli, Riccardo Gerosa, Michela Cinquini [...]

Tumori Journal

Retricted access

Research article

First published 2025

Timing of bone-modifying agents after bone metastasis diagnosis and time to first skeletal-related event: A systematic review and study-level correlation analysis

Junya Sato, Tatsuki Ikeda, Satoru Nihei [...]

Journal of Oncology Pharmacy Practice

Retricted access

Research article

First published 2020-6

Bone modifying agents for patients with bone metastases from breast cancer managed in routine practice setting: Treatment patterns and outcome

Jamal Zekri, Kamel Farag, Osama Yousof [...]

Journal of Oncology Pharmacy Practice

Free access

Review article

First published 2012-4

Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid

Matti Aapro, Fred Saad

Therapeutic Advances in Urology

Free access

Article commentary

First published 2023-02-14

Bone modifying agents in postmenopausal breast cancer patients treated with aromatase inhibitors: beyond bone protection?

Andrea Villasco, Carola Minella, Valentina Elisabetta Bounous [...]

Breast Disease

Retricted access

Brief report

First published 2011-10

Feline Bone Marrow-Derived Mesenchymal Stem Cells Express Several Pluripotent and Neural Markers and Easily Turn into Neural-Like Cells by Manipulation with Chromatin Modifying Agents and Neural Inducing Factors

Zhiying Zhang, Dennis J. Maiman, Shekar N. Kurpad [...]

Cellular Reprogramming

Retricted access

Research article

First published 2024-10

Efficacy and safety of bone management agents administered at 12 weeks vs. 4 weeks in patients with bone metastases: A systematic review

Junya Sato, Makoto Kodaira, Hiroyuki Harada [...]

Journal of Oncology Pharmacy Practice

Search results